These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31101577)

  • 21. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
    Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J
    BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer.
    Del Re M; Crucitta S; Brighi N; Kinspergher S; Mercinelli C; Rizzo M; Conteduca V; Rebuzzi SE; Beninato T; Venturi G; Doni L; Verzoni E; Puglisi S; Landriscina M; Porta C; Manfredi F; Caffo O; De Giorgi U; Fogli S; Danesi R
    Clin Genitourin Cancer; 2024 Oct; 22(5):102147. PubMed ID: 39030142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.
    Cirkel GA; Hamberg P; Sleijfer S; Loosveld OJL; Dercksen MW; Los M; Polee MB; van den Berkmortel F; Aarts MJ; Beerepoot LV; Groenewegen G; Lolkema MP; Tascilar M; Portielje JEA; Peters FPJ; Klümpen HJ; van der Noort V; Haanen JBAG; Voest EE;
    JAMA Oncol; 2017 Apr; 3(4):501-508. PubMed ID: 27918762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
    Iacovelli R; Cossu Rocca M; Galli L; Sabbatini R; De Giorgi U; Santini D; Facchini G; Mosca A; Atzori F; Zucali P; Fornarini G; Massari F; Buti S; Ricotta R; Masini C; Toscani I; Biasco E; Guida A; Lolli C; De Lisi D; Rossetti S; Terrone C; Scartozzi M; Miggiano C; Pastorino A; Bersanelli M; Carlo-Stella G; Pinto C; Nobili E; Nolè F; Tortora G; Porta C
    Anticancer Drugs; 2018 Aug; 29(7):705-709. PubMed ID: 29846246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
    Géczi L; Bodoky G; Rokszin G; Fábián I; Torday L
    Pathol Oncol Res; 2020 Oct; 26(4):2201-2207. PubMed ID: 32291570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
    Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ
    Lancet Oncol; 2016 Mar; 17(3):378-388. PubMed ID: 26794930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
    Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.
    Uhlig A; Uhlig J; Trojan L; Woike M; Leitsmann M; Strauß A
    Future Oncol; 2021 Jan; 17(1):45-56. PubMed ID: 33275038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ; Tian J; Chen X; Wang D; Li CL
    Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.
    Huang WK; Liaw CC; Pang ST; Chuang CK; Chiang YJ; Wu CT; Chang YH; Wang HM; Lin YC; Hsieh JJ; Ou LY; Tsai SI; Yang CH; Yang CT; Chang JW
    Chang Gung Med J; 2012; 35(5):402-7. PubMed ID: 23127345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).
    Rodriguez-Vida A; Bamias A; Esteban E; Saez MI; Lopez-Brea M; Castellano D; Caballero C; Gonzalez-Larriba JL; Calvo E; Macia S; Ravaud A; Bellmunt J
    BJU Int; 2020 Nov; 126(5):559-567. PubMed ID: 32654362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
    Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
    Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
    Lolli C; Gallà V; Schepisi G; Barone D; Burgio SL; Maugeri A; Vertogen B; Amadori D; De Giorgi U
    Oncologist; 2017 Jul; 22(7):784-e74. PubMed ID: 28546463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.
    Goebell PJ; Doehn C; Grüllich C; Grünwald V; Steiner T; Ehneß R; Welslau M
    Future Oncol; 2017 Jul; 13(17):1463-1471. PubMed ID: 28523933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ).
    Schostak M; de Geeter P; Decker T; Resch A; Quiering C; Schmitz S
    Urol Int; 2020; 104(3-4):263-268. PubMed ID: 31726458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
    Bastin J; Werbrouck E; Verbiest A; Punie K; Bechter O; Woei-A-Jin FJ; Wolter P; Wildiers H; Lerut E; Dumez H; Decallonne B; Clement P; Vanderschueren D; Albersen M; Oyen R; Schöffski P; Beuselinck B
    Acta Clin Belg; 2019 Jun; 74(3):169-179. PubMed ID: 29774795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.